Ginkgo Bioworks Q2 FY26 GAAP net loss widens to $57 million; revenue drops 48% to $20 million
Reuters2026/08/05 20:46- Ginkgo Bioworks posted Q2 2026 revenue of USD 20 million, down 48% on ongoing program rationalization tied to restructuring.
- GAAP net loss from continuing operations widened to USD 57 million.
- Adjusted EBITDA loss widened to USD 36 million.
- Cash, cash equivalents and marketable securities totaled USD 302 million at June 30, 2026; full-year cash burn outlook reaffirmed at USD 150-125 million.
- Won government-backed autonomous lab work at MIT, Caltech, Northwestern and the University of Maryland; began a USD 47 million build at PNNL’s EMSL.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
OPEC+ agrees to keep oil output policy unchanged for October
US military strikes Iranian oil tanker, triggering geopolitical risks as Brent crude nears $97 mark
Following the US military's attack on Iranian oil tankers and Iran's announcement of new restricted navigation zones outside the Strait of Hormuz, market concerns over prolonged disruptions in key energy transport routes have intensified, leading to a sharp rise in international oil prices.
Geopolitical tensions overshadowing production cuts: OPEC+ maintains quotas unchanged, paper adjustments fail to resolve physical supply dilemmas
OPEC+ major oil producers, led by Saudi Arabia and Russia, held a monthly video conference last Sunday and decided to keep the crude oil production quota for October unchanged, continuing the previous tone of stable production following a series of symbolic production increases.
IX Biopharma seeks SGX-ST trading halt lift for shares in Singapore
Crypto prices
More
